Amneal Pharmaceuticals (AMRX) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free AMRX Stock Alerts $6.86 +0.08 (+1.18%) (As of 10:04 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 8:06 AM | americanbankingnews.comShort Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 29.5%May 30 at 2:28 AM | americanbankingnews.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $8.25 Consensus Price Target from AnalystsMay 29 at 4:30 AM | marketbeat.com212,700 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Swiss National BankSwiss National Bank acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 212,700 shares of the company's stock, valued at approximately $1,291,000. Swiss National BMay 28 at 1:25 PM | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Shares Up 6.4%Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 6.4%May 27 at 1:52 AM | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have earned an average rating of "Buy" from the four research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1-year taMay 22, 2024 | marketwatch.comAmneal Pharmaceuticals Begins Supplying Generic Version of NarcanMay 22, 2024 | businesswire.comAmneal to Participate at Upcoming Investor ConferenceMay 22, 2024 | businesswire.comAmneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of CaliforniaMay 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Raises Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 271.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 546,537 shares of the company's stock after buying anMay 20, 2024 | finance.yahoo.comInsider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX)May 15, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High at $6.95Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 52-Week High at $6.95May 14, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Drop in Short InterestAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totalling 2,370,000 shares, a decline of 15.4% from the April 15th total of 2,800,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is currently 1.5 days. Approximately 2.3% of the company's stock are short sold.May 13, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)May 9, 2024 | marketbeat.comLSV Asset Management Has $6.61 Million Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)LSV Asset Management decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 23.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,089,300 shares of thMay 6, 2024 | markets.businessinsider.comAssessing Amneal Pharmaceuticals: Insights From 4 Financial AnalystsMay 6, 2024 | finance.yahoo.comAmneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)May 6, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00The Goldman Sachs Group upped their target price on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a "buy" rating in a report on Monday.May 6, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Reaffirmed by Truist FinancialTruist Financial restated a "buy" rating and issued a $9.00 target price (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday.May 6, 2024 | markets.businessinsider.comAmneal Pharmaceuticals: A Strong Buy on Robust Growth and Promising PipelineMay 4, 2024 | msn.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comAmneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 3, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High at $6.90Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High at $6.90May 3, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2024 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.530-0.630 for the period, compared to the consensus estimate of 0.580. The company also issued revenue guidance of $2.6 billionillion-$2.7 billionillion, compared to the consensus estimate of $2.6 billionillion.May 3, 2024 | msn.comGeneric Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit SettlementMay 3, 2024 | msn.comAmneal stock climbs on Q1 report, opioid settlement updateMay 3, 2024 | seekingalpha.comAmneal Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | msn.comAMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 3, 2024 | reuters.comDrugmaker Amneal agrees to $270 million U.S. opioid settlementMay 3, 2024 | washingtonpost.comAmneal: Q1 Earnings SnapshotMay 3, 2024 | businesswire.comAmneal Reports First Quarter 2024 Financial ResultsMay 2, 2024 | msn.comAmneal Pharmaceuticals Q1 2024 Earnings PreviewMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)April 30, 2024 | msn.comCalifornia is joining with a New Jersey company to make a generic opioid overdose reversal drugApril 30, 2024 | msn.comCalifornia teams with Amneal Pharma for cheaper, generic version of NarcanApril 29, 2024 | msn.comCalifornia is joining with a New Jersey company to buy a generic opioid overdose reversal drugApril 25, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Trading Down 7.1%Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 7.1%April 25, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Sells 146,925 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Allspring Global Investments Holdings LLC lessened its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 51.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 137,764 sharesApril 24, 2024 | marketwatch.comAmneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone SprayApril 24, 2024 | markets.businessinsider.comAmneal's OTC Naloxone Nasal Spray Receives FDA Approval For Opioid Overdose Emergency TreatmentApril 24, 2024 | businesswire.comAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseApril 16, 2024 | businesswire.comAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineApril 15, 2024 | finance.yahoo.comAmneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past weekApril 14, 2024 | marketbeat.comPhocas Financial Corp. Buys Shares of 714,890 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Phocas Financial Corp. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 714,890 shares of the company's stock, valued at approximately $4,339,0April 14, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 15.9% in MarchAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 2,400,000 shares, a growth of 15.9% from the March 15th total of 2,070,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 2.2% of the company's stock are sold short.April 11, 2024 | finance.yahoo.comAlkermes' Innovations Are Transforming Mental Health TreatmentsApril 10, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 1.9%Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 1.9%April 10, 2024 | businesswire.comAmneal to Report First Quarter 2024 Results on May 3, 2024April 9, 2024 | stocknews.com3 Lucrative Pharma Stocks to Diversify Your InvestmentsApril 9, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 2.2%Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 2.2%April 8, 2024 | msn.comBausch Health drops after suing Amneal Pharma over Xifaxan generic Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution AMRX Media Mentions By Week AMRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼0.920.80▲Average Medical News Sentiment AMRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼83▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RCKT News Today ZLAB News Today AMPH News Today CPRX News Today DCPH News Today GERN News Today GLPG News Today VERA News Today KROS News Today AGIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe Exchange[Urgent!] Generational Wealth GameplanCrypto 101 MediaWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
